닫기
18.119.134.140
18.119.134.140
close menu
}
KCI 등재 SCOPUS
CASE REPORT : Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis
( Seong Woo Go ) , ( Boo Kyeong Kim ) , ( Sung Hak Lee ) , ( Tae Jung Kim ) , ( Joo Yeon Huh ) , ( Jong Min Lee ) , ( Jick Hwan Hah ) , ( Dong Whi Kim ) , ( Min Jung Cho ) , ( Tae Wan Kim ) , ( Ji Young Kang )
UCI I410-ECN-0102-2014-500-002062504
이 자료는 4페이지 이하의 자료입니다.
* 발행 기관의 요청으로 무료로 이용 가능한 자료입니다.

Imatinib mesylate is a targeted therapy that acts by inhibiting tyrosine kinase of the bcr-abl fusion oncoprotein, which is specific to chronic myeloid leukemia (CML), and the c-transmembrane receptor, which is specific to gastrointestinal stromal tumors. Interstitial pneumonitis is a rare adverse event of imatinib therapy. It is clinically difficult to distinguish from infectious pneumonia, which can frequently occur due to the underlying disease. The standard treatment for imatinib-induced pneumonitis is to discontinue the medication and optionally administer corticosteroids. However, there are a few cases of successful retrial with imatinib. We describe a case of successful rechallenge of imatinib in a patient with imatinib-induced interstitial pneumonitis and CML without a recurrence of the underlying disease after 3 months of follow-up.

[자료제공 : 네이버학술정보]
×